FDA clears IND application for ORM-1153 for Ph 1 study in patients with R/R AML and other hematologic malignancies August 25, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer August 25, 2026
IDMC recommends to continue patient enrolment in Ph 1 ZIMA-101 trial in solid tumor patients August 25, 2026
FDA Fast Track Designation Granted to ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma August 25, 2026
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline August 25, 2026
First Patient Dosed in MODeFIRe-1 Ph 2 Study of MRT-2359 + Apalutamide in Patients with AR Mutation-Positive Metastatic CRPC August 25, 2026
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer August 25, 2026
AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in LBCL August 25, 2026
Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors August 25, 2026
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline August 25, 2026
TME Pharma enters the final evaluation phase of advanced discussions with two potential partners for a license agreement aimed at Ph 2 development of NOX-A12 August 25, 2026
SUPRAME topline data disclosure for the final PFS analysis expected in H1 2027, followed by BLA submission in 2027 August 25, 2026
Enrollment opens in Ph 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101 August 25, 2026
Ph 3 INTerpath-001 Trial of Intismeran Autogene + KEYTRUDA Met RFS and DMFS Endpoints in Patients With Completely Resected Stage IIB-IV Melanoma August 25, 2026
FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study August 25, 2026
FDA Fast Track Designation for BH-30643 for the Treatment of Advanced EGFR C797S-positive NSCLC August 25, 2026
FDA Fast Track Designation for ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer August 25, 2026
FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors August 25, 2026
European Commission approves TECVAYLI (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma August 25, 2026
